Canada's NeuPath Health Q4 revenue rises on increased patient visits, new services

NeuPath Health

26/03/2026 11:41

Overview

Canada pain clinic operator's Q4 revenue rose 17% yr/yr

Adjusted EBITDA for Q4 increased 9% yr/yr, marking 28th consecutive positive quarter

Clinic revenue growth driven by more patient visits, new services, and improved physician utilization

Outlook

NeuPath expects continued growth and margin improvement in 2026

Company plans to expand to new locations and increase availability of Arthrosamid procedures

NeuPath will report physical capacity utilization metrics quarterly starting in 2026

Result Drivers

PATIENT VOLUME - Increased patient visits drove higher clinic revenue, according to the company

NEW SERVICES - Launch of Arthrosamid and growth from fluoroscopy procedures contributed to revenue growth

PHYSICIAN UTILIZATION - Improved physician utilization and capacity optimization supported revenue gains

Company press release: ID:nBw5mZYS9a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
C$22.10 mln
C$23.50 mln (1 Analyst)
Q4 Adjusted EBITDA
C$1 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for NeuPath Health Inc is C$0.50, about 4.2% above its March 25 closing price of C$0.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)